Evidence map›Paper›PMID 21827753›Full record

ReviewFEBS letters2011

Unraveling the enigmatic complexities of BRMS1-mediated metastasis suppression.

Douglas R Hurst, Danny R Welch

Open access · greenAbstract readReview
In one paragraph

Review in FEBS letters, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.

  1. Bioscience reports · 2017
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Nanoparticle-mediated targeted drug delivery for breast cancer treatment.Biochimica et biophysica acta. Reviews on cancer · 2019
    Review
  8. Article
  9. The fundamental role of miR-10b in metastatic cancer.American journal of cancer research · 2018
    Review
  10. Article
  11. Structural insights into the assembly of the histone deacetylase-associated Sin3L/Rpd3L corepressor complex.Proceedings of the National Academy of Sciences of the United States of America · 2015
    Article
  12. Article
  13. Article
  14. Microenvironmental Influences on Metastasis Suppressor Expression and Function during a Metastatic Cell's Journey.Cancer microenvironment : official journal of the International Cancer Microenvironment Society · 2014
    Article
  15. Article
  16. Article
  17. Review
  18. Lung cancer with gastrointestinal metastasis - review of theories of metastasis with three rare case descriptions.Cancer microenvironment : official journal of the International Cancer Microenvironment Society · 2013
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Douglas R HurstDepartment of Pathology, University of Alabama at Birmingham, Birmingham, AL 35294-0019, USA. DHurst@uab.edu
Danny R Welch
The University of Kansas Cancer Center · USUniversity of Alabama at Birmingham · US

Funding

UAB Rexinoids for Breast Cancer PreventionP50CA089019 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI GRIZZLE, WILLIAM E. · 2000 to 2011
$26.0M
MOLECULAR REGULATION OF BREAST CANCER METASTASISR01CA087728 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI WELCH, DANNY R. · 2000 to 2008
$2.7M
KISS1: Defining Mechanisms for Antimetastatic TherapyR01CA134981 · NCI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI WELCH, DANNY R. · 2009 to 2014
$1.5M
METASTASIS SUPPRESSOR GENES IN HUMAN CUTANEOUS MELANOMAR01CA062168 · NCI · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI WELCH, DANNY R · 1994 to 1999
–
NCI NIH HHS CA062168NCI NIH HHS CA087728NCI NIH HHS CA089019NCI NIH HHS CA134981NCI NIH HHS P50 CA089019NCI NIH HHS R01 CA062168NCI NIH HHS R01 CA087728NCI NIH HHS R01 CA134981
6 · The paper itself

Abstract

Expression of BRMS1 causes dramatic suppression of metastasis in multiple in vivo model systems. As we gain further insight into the biochemical mechanisms of BRMS1, we appreciate the importance of both molecular and cellular context for functional metastasis suppression. BRMS1 associates with large chromatin remodeling complexes including SIN3:HDAC which are powerful epigenetic regulators of gene expression. Additionally, BRMS1 inhibits the activity of NFκB, a well-known transcription factor that plays significant roles in tumor progression. Moreover, BRMS1 coordinately regulates the expression of metastasis-associated microRNA known as metastamir. How these biochemical mechanisms and biological pathways are linked, either directly or indirectly, and the influence of molecular and cellular context, are critical considerations for the discovery of novel therapeutic targets for the most deadly aspect of tumor progression-metastasis.

Indexed as

Epigenesis, GeneticGene Expression Regulation, NeoplasticAnimalsHumansMicroRNAsNeoplasm MetastasisNeoplasm ProteinsNeoplasms, ExperimentalNF-kappa BRepressor ProteinsRNA, NeoplasmSin3 Histone Deacetylase and Corepressor ComplexTumor Suppressor ProteinsBRMS1 protein, humanMicroRNAsNeoplasm ProteinsNF-kappa BRepressor ProteinsRNA, NeoplasmSin3 Histone Deacetylase and Corepressor ComplexTumor Suppressor Proteins

Identifiers

PMID21827753
PMCPMC3195837
OpenAlexW1981985776

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.